---
title: "Novavax Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286471643.md"
description: "Novavax Inc. (NVAX) shares rose 1.30% to $9.35 on a strong trading day, outperforming competitors like Johnson & Johnson (up 0.16%), while Pfizer and Merck saw declines. The NASDAQ Composite Index increased by 0.88% and the Dow Jones by 0.75%. Novavax remains 21.89% below its 52-week high of $11.97 reached on February 26. Trading volume was 4.6 million, surpassing the 50-day average of 4.4 million."
datetime: "2026-05-14T21:27:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286471643.md)
  - [en](https://longbridge.com/en/news/286471643.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286471643.md)
---

# Novavax Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Novavax Inc. (NVAX) advanced 1.30% to $9.35 Thursday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index rising 0.88% to 26,635.22 and the Dow Jones Industrial Average rising 0.75% to 50,063.46.

Novavax Inc. closed 21.89% short of its 52-week high of $11.97, which the company reached on February 26th.

The stock outperformed some of its competitors Thursday, as Johnson & Johnson (JNJ) rose 0.16% to $230.80, Pfizer Inc. (PFE) fell 0.81% to $25.75, and Merck & Co. Inc. (MRK) fell 0.04% to $113.41.

Trading volume (4.6 M) eclipsed its 50-day average volume of 4.4 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 14, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-14-26 1727ET

### Related Stocks

- [NVAX.US](https://longbridge.com/en/quote/NVAX.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)